Evidence map›Paper›PMID 37335976›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2023

Pulsed field ablation using focal contact force-sensing catheters for treatment of atrial fibrillation: acute and 90-day invasive remapping results.

Ante Anić, Thomas Phlips, Toni Brešković, Pieter Koopman, Steven Girouard, Vikramaditya Mediratta, Zrinka Jurišić, Ivan Sikirić, Lucija Lisica, Johan Vijgen

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04523545 (Safety & Performance Study of the Centauri System for Patients With Atrial Fibrillation), which is not on this map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
13.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04523545 naunknown statusnot on this map

Safety & Performance Study of the Centauri System for Patients With Atrial Fibrillation

TypeinterventionalSponsorGalaxy Medical, Inc.Ran2020 to 2023Enrolled200ConditionsAtrial FibrillationArmscardiac ablation
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 63 citations in OpenAlex.

  1. First-in-human experience from RESET-AF (Rapid onE-Shot Electroporation Trial for Atrial Fibrillation).Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Trial
  2. Safety and effectiveness of the TactiFlex duo system: 6-month results of the FOCALFLEX study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  3. Article
  4. Focal pulsed field ablation for complex ventricular arrhythmias after prior failed or intraprocedurally ineffective radiofrequency ablation.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  5. Impact of catheter design on lesion dimensions during focal-bipolar pulsed field ablation: an in vitro potato model study.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Latest Advances and Ongoing Challenges in Pulsed Field Ablation.Arrhythmia & electrophysiology review · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Controversy: pulsed field ablation is the standard technique for all the candidates for atrial fibrillation ablation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Review
  18. Article
  19. Review
  20. Dual energy for pulmonary vein isolation using focal ablation technology integrated with a three-dimensional mapping system: SmartfIRE 12-month results.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ante AnićHeart and vascular center, Klinički Bolnički Centar (KBC) Split, Spinčićeva ul. 1, Split 21000, Croatia.ORCID 0000-0002-6864-3999
Thomas PhlipsJessa Ziekenhuis, Hasselt, Belgium.ORCID 0000-0002-4303-9226
Toni BreškovićHeart and vascular center, Klinički Bolnički Centar (KBC) Split, Spinčićeva ul. 1, Split 21000, Croatia.ORCID 0000-0001-7266-2087
Pieter KoopmanJessa Ziekenhuis, Hasselt, Belgium.ORCID 0000-0002-6373-180X
Steven GirouardGalvanize Therapeutics, Inc. (previously Galaxy Medical), Redwood City, CA, USA.
Vikramaditya MedirattaGalvanize Therapeutics, Inc. (previously Galaxy Medical), Redwood City, CA, USA.ORCID 0009-0002-9280-6935
Zrinka JurišićHeart and vascular center, Klinički Bolnički Centar (KBC) Split, Spinčićeva ul. 1, Split 21000, Croatia.ORCID 0000-0001-7583-9036
Ivan SikirićHeart and vascular center, Klinički Bolnički Centar (KBC) Split, Spinčićeva ul. 1, Split 21000, Croatia.
Lucija LisicaHeart and vascular center, Klinički Bolnički Centar (KBC) Split, Spinčićeva ul. 1, Split 21000, Croatia.ORCID 0000-0003-1904-0259
Johan VijgenJessa Ziekenhuis, Hasselt, Belgium.ORCID 0000-0003-4928-4836
Klinički Bolnički Centar Split · HRJessa Hospital · BE

Funding

Galvanize Therapeutics
6 · The paper itself

Abstract

aimsPulsed field ablation (PFA) has emerged as a promising alternative to thermal ablation for treatment of atrial fibrillation (AF). We report performance and safety using the CENTAURI™ System (Galvanize Therapeutics) with three commercial, focal ablation catheters. METHODS AND

resultsECLIPSE AF (NCT04523545) was a prospective, single-arm, multi-centre study evaluating safety and acute and chronic pulmonary vein isolation (PVI) durability using the CENTAURI System in conjunction with the TactiCath SE, StablePoint, and ThermoCool ST ablation catheters. Patients with paroxysmal or persistent AF were treated at two centres. Patients were analysed in five cohorts based upon ablation settings, catheter, and mapping system. Pulsed field ablation was performed in 82 patients (74% male, 42 paroxysmal AF). Pulmonary vein isolation was achieved in 100% of pulmonary veins (322/322) with first-pass isolation in 92.2% (297/322). There were four serious adverse events of interest (three vascular access complications and one lacunar stroke). Eighty patients (98%) underwent invasive remapping. Pulsed field ablation development Cohorts 1 and 2 showed a per-patient isolation rate of 38% and 26% and a per-PV isolation rate of 47% and 53%, respectively. Optimized PFA Cohorts 3-5 showed a per-patient isolation rate of 60%, 73%, and 81% and a per-PV isolation rate of 84%, 90%, and 92%, respectively.

conclusionECLIPSE AF demonstrated that optimized PFA using the CENTAURI System with three commercial, contact force-sensing, solid-tip focal ablation catheters resulted in transmural lesion formation and high proportion of durable PVI with a favourable safety profile, thus providing a viable treatment option for AF that integrates with contemporary focal ablation workflows.

Indexed as

Atrial FibrillationCatheter AblationPulmonary VeinsCathetersFemaleFocal AdhesionsHumansMaleProspective StudiesRecurrenceTreatment OutcomeAtrial fibrillationFocal catheterPulmonary vein isolationPulsed electric fieldsPulsed field ablationRemapping

Identifiers

PMID37335976
PMCPMC10279421
OpenAlexW4381251654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.